literature

HIV mutation literature information.

Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.

PMID: 31751428 2019 PloS one

Table: A98G

High Levels of HIV-1 Drug Resistance in Children Who Acquired HIV Infection Through Mother to Child Transmission in the Era of Option B+, Haiti, 2013 to 2014.

PMID: 30640198 2019 The Pediatric infectious disease journal

Result: Twenty-nine (9.5%) of the children had additional NNRTI mutations (A98G, E138A/G/K/Q, H221Y, and M230L) that confer resistance to second generation NNRTI drugs etravirine and rilpivirine.

Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.

PMID: 30650082 2019 PloS one

Result: For a number of TDRMs, no loss could be observed during the observation period (S1 Table) and, according to their maximal duration of observation, the following TDRMs seem to survive for lengthy periods in the absence of ART: the NRTI resistance mutations D67N (5.9 years), K70R (6.9 years), F77L (10.2 years), T215E (5.9 years) and K219Q (5.9 years), the NNRTI resistance mutations A98G (6.5 years) and Y188L (5.9 years) as well as the PI mutations I54L (5.9 years) and L90M (8.4 years) (S1 Table).

HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.

PMID: 31117863 2019 Journal of the International Association of Providers of AIDS Care

Abstract: M184V, M41L, D67N, G190A, A98G, and K103N were the most common mutations seen.

Table: A98G

Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.

PMID: 31443633 2019 BMC infectious diseases

Result: For NNRTIs, the most prevalent drug resistance mutations were K103 N (1.59%), V179D + K103R (1.33%), Y181C (0.80%), V108I (0.53%), Y188L (0.53%), G190A (0.53%), H221Y (0.53%), Y318F (0.53%), A98G (0.27%), V106A (0.27%), E138A (0.27%), E138R (0.27%), Y188C (0.27%) and M230 L (0.27%).

HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.

PMID: 31699949 2019 Acta medica Indonesiana

Abstract: The common NRTI mutations were M184VI and K65R, while NNRTI mutations were Y181CFGVY, K103N, A98AG, E138GQ and G190AGS.

Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam.

PMID: 31190911 2019 Infection and drug resistance

Table: A98G

High prevalence of HIV-1 transmitted drug resistance among therapy-naive Burmese entering travelers at Dehong ports in Yunnan, China.

PMID: 29739342 2018 BMC infectious diseases

Result: For NNRTI resistance-associated mutations, V179D/T was identified as the major mutation (20 cases), and the other 6 types of mutation were E138A, A98G, K101P, K103 N, Y181H and Y188H.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

PMID: 29566538 2018 Antiviral chemistry & chemotherapy

Method: Plasma samples contained a median of 3 [Q1-Q3: 2-4] NNRTI-associated drug resistance mutations which included A98G, L100I, K101E/H, K103N/S, V106M, V108I, E138A/K, V179D/E Y181C, Y188L/C, G190A, H221Y, P225H, F227L, and M230L.

Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.

PMID: 29084434 2018 AIDS research and human retroviruses

Introduction: The most common mutations detected were Y181C, K103N, G190A, A98G, K101E, V108I, H221Y, M230L, and P225H.

Browser Board

Co-occurred Entities

Filtrator